vs
Side-by-side financial comparison of Orchid Island Capital, Inc. (ORC) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $38.5M, roughly 1.8× Orchid Island Capital, Inc.). Orchid Island Capital, Inc. runs the higher net margin — 268.7% vs -49.0%, a 317.7% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 372.6%).
Orchid Island Capital, Inc. is a U.S.-based specialty finance company operating as a real estate investment trust. It primarily invests in residential mortgage-backed securities, including agency and non-agency products, targeting consistent risk-adjusted returns for its investors across U.S. fixed income markets.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
ORC vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.5M | $70.6M |
| Net Profit | $103.4M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | — | -56.7% |
| Net Margin | 268.7% | -49.0% |
| Revenue YoY | 372.6% | 81958.1% |
| Net Profit YoY | 1764.9% | 54.9% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.5M | — | ||
| Q3 25 | $26.9M | $70.6M | ||
| Q2 25 | $23.2M | — | ||
| Q1 25 | $19.7M | — | ||
| Q3 24 | $340.0K | — | ||
| Q2 24 | $-697.0K | — | ||
| Q1 24 | $-2.5M | — | ||
| Q4 22 | $2.4M | — |
| Q4 25 | $103.4M | — | ||
| Q3 25 | $72.1M | $-34.6M | ||
| Q2 25 | $-33.6M | — | ||
| Q1 25 | $17.1M | — | ||
| Q3 24 | $17.3M | — | ||
| Q2 24 | $-5.0M | — | ||
| Q1 24 | $19.8M | — | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -56.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | 268.7% | — | ||
| Q3 25 | 267.8% | -49.0% | ||
| Q2 25 | -145.0% | — | ||
| Q1 25 | 86.9% | — | ||
| Q3 24 | 5094.1% | — | ||
| Q2 24 | 714.3% | — | ||
| Q1 24 | -794.2% | — | ||
| Q4 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $665.9M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $503.0M |
| Total Assets | $11.7B | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $665.9M | — | ||
| Q3 25 | $583.9M | $490.9M | ||
| Q2 25 | $440.8M | — | ||
| Q1 25 | $396.4M | — | ||
| Q3 24 | $322.1M | — | ||
| Q2 24 | $241.0M | — | ||
| Q1 24 | $190.4M | — | ||
| Q4 22 | $205.7M | — |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.1B | $503.0M | ||
| Q2 25 | $912.0M | — | ||
| Q1 25 | $855.9M | — | ||
| Q3 24 | $656.0M | — | ||
| Q2 24 | $555.9M | — | ||
| Q1 24 | $481.6M | — | ||
| Q4 22 | $438.8M | — |
| Q4 25 | $11.7B | — | ||
| Q3 25 | $9.1B | $577.1M | ||
| Q2 25 | $7.6B | — | ||
| Q1 25 | $7.3B | — | ||
| Q3 24 | $5.9B | — | ||
| Q2 24 | $4.9B | — | ||
| Q1 24 | $4.2B | — | ||
| Q4 22 | $3.9B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.4M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 1.16× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.4M | — | ||
| Q3 25 | $28.0M | $-84.6M | ||
| Q2 25 | $18.4M | — | ||
| Q1 25 | $25.8M | — | ||
| Q3 24 | $-14.8M | — | ||
| Q2 24 | $19.3M | — | ||
| Q1 24 | $45.0M | — | ||
| Q4 22 | $289.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | 1.16× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.51× | — | ||
| Q3 24 | -0.86× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.28× | — | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
